<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720523</url>
  </required_header>
  <id_info>
    <org_study_id>M14-663</org_study_id>
    <nct_id>NCT02720523</nct_id>
  </id_info>
  <brief_title>A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs</brief_title>
  <acronym>SELECTSUNRISE</acronym>
  <official_title>A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in
      Japanese Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable
      Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an
      Inadequate Response to csDMARDs.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Anticipated">July 19, 2020</completion_date>
  <primary_completion_date type="Actual">August 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving American College of Rheumatology (ACR) 20 response at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in Functional Assessment of Chronic Illness Therapy (FACIT-F)</measure>
    <time_frame>Week 12</time_frame>
    <description>FACIT-F is participant questionnaire with 13 indexes rated on a 5 point scale. The indexes generally relate to the participant's level of fatigue during the past 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 20 Response Rate</measure>
    <time_frame>Week 1</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 Response Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>Week 12</time_frame>
    <description>HAQ-DI is a participant questionnaire with questions regarding the participant's illness and how it affect their daily life activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in Rheumatoid Arthritis Work Instability Scale (RA-WIS)</measure>
    <time_frame>Week 12</time_frame>
    <description>RA-WIS is a participant questionnaire containing 23 questions relating to the participant's functioning in their work environment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving Clinical Remission (CR) based on DAS28 (CRP)</measure>
    <time_frame>Week 12</time_frame>
    <description>CR based on DAS28 (CRP) response rate is defined as DAS28 (CRP) less than 2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in Disease Activity Score (DAS)28 C-Reactive Protein (CRP)</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 Response Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in Short-Form 36 (SF-36) Physical Component Score (PCS)</measure>
    <time_frame>Week 12</time_frame>
    <description>SF-36 is a 36 item participant questionnaire with questions regarding participant health and daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving Low Disease Activity (LDA) based on DAS28 (CRP)</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving low disease activity as defined by a clinical response DAS28[CRP] less than or equal to 3.2. The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score greater than 5.1 indicates high disease activity, a DAS28 score less than or equal to 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (week 0) in morning stiffness (severity)</measure>
    <time_frame>Week 12</time_frame>
    <description>Morning Stiffness severity is determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. The severity score is based on a single 0 to 10 rating scale with 0 indicating &quot;No morning stiffness&quot; and 10 indicating &quot;Worst possible morning stiffness&quot;</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ABT-494 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-494 Dose A once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by ABT-494 Dose A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose A once daily up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-494 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-494 Dose B once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-494 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-494 Dose C once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by ABT-494 Dose C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose C once daily up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by ABT-494 Dose B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose B once daily up to regulatory approval of RA indication in Japan (Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral formulation</description>
    <arm_group_label>Placebo followed by ABT-494 Dose A</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494 Dose B</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Oral formulation</description>
    <arm_group_label>ABT-494 Dose A</arm_group_label>
    <arm_group_label>ABT-494 Dose B</arm_group_label>
    <arm_group_label>ABT-494 Dose C</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494 Dose A</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494 Dose B</arm_group_label>
    <arm_group_label>Placebo followed by ABT-494 Dose C</arm_group_label>
    <other_name>Upadacitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis (RA) for &gt;= 3 months who also fulfill the 2010
             American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
             classification criteria for RA.

          -  Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic
             drug (csDMARD) therapy &gt;= 3 months and on a stable dose for &gt; or = 4 weeks prior to
             the first dose of study drug.

          -  Subject has &gt;= 6 swollen joints (based on 66 joint counts) and &gt;= 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biological disease-modifying
             anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects)
             after the required washout period. Specifically, prior to enrollment:

               1. Subjects with limited exposure to bDMARD (&lt; 3 months) OR

               2. Subjects who are responding to bDMARD therapy but had to discontinue due to
                  intolerability (regardless of treatment duration).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor

          -  Subjects who are considered inadequate responders (lack of efficacy) to bDMARD
             therapy, after minimum 3 months treatment, as determined by the Investigator.

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including
             ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hosp</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospi</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Asahikawa Medical Center</name>
      <address>
        <city>Asahikawa</city>
        <zip>070-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katayama Orthopedic Rheum Clin</name>
      <address>
        <city>Asahikawa</city>
        <zip>078-8243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Chiba-East-Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugimoto Rheum and Int Med</name>
      <address>
        <city>Fukui</city>
        <zip>910-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamanomachi Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shono Rheumatism Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Rheumatology Clinic</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital</name>
      <address>
        <city>Ichinomiya</city>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Mayflower Hospital</name>
      <address>
        <city>Kato</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Osaka Minami Med Ctr</name>
      <address>
        <city>Kawachinagano</city>
        <zip>586-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Occup &amp; Environ Health</name>
      <address>
        <city>Kitakyushu</city>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Rheumatology Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-5515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Orthopaedic Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marunouchi Hospital</name>
      <address>
        <city>Matsumoto</city>
        <zip>390-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yu Family Clinic</name>
      <address>
        <city>Miyagi</city>
        <zip>981-0112</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Keiai Kai</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaoka Red Cross Hospital</name>
      <address>
        <city>Nagaoka</city>
        <zip>940-2108</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP Red Cross Nagoya Daiichi</name>
      <address>
        <city>Nagoya</city>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kondo Clinic for Ortho &amp; Rheum</name>
      <address>
        <city>Nagoya</city>
        <zip>464-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oribe Clinic of Rheumatology</name>
      <address>
        <city>Oita</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama City Gen Med Ctr</name>
      <address>
        <city>Okayama</city>
        <zip>700-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyashita Rheumatology Clinic</name>
      <address>
        <city>Omura</city>
        <zip>856-0836</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Sagamihara Natl Hosp</name>
      <address>
        <city>Sagamihara</city>
        <zip>252-0315</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sagawa Akira Rheumatology Clin</name>
      <address>
        <city>Sapporo</city>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>980-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hikarigaoka Spellman Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>983-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Rheumatic Center</name>
      <address>
        <city>Shibata</city>
        <zip>957-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokito Clinic Rheum and Ortho</name>
      <address>
        <city>Shimonoseki</city>
        <zip>752-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honjo Rheumatism Clinic</name>
      <address>
        <city>Takaoka</city>
        <zip>933-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Hospital</name>
      <address>
        <city>Takasaki</city>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takikawa Municipal Hospital</name>
      <address>
        <city>Takikawa</city>
        <zip>073-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Luke's International Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Uchida Cli</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Tokyo Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho Univ. Ohashi Med. Center</name>
      <address>
        <city>Tokyo</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setagaya Rheumatic Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>156-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Womens Med Univ Hosp</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hosp</name>
      <address>
        <city>Tokyo</city>
        <zip>173-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oki Medical Clinic</name>
      <address>
        <city>Tomakomai</city>
        <zip>053-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toneyama National Hospital</name>
      <address>
        <city>Toyonaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>ABT-494</keyword>
  <keyword>Japanese</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

